Arbor Biotechnologies
Arbor Biotechnologies is a gene editing company developing genomic medicines, with over 100 employees and $305M in funding. It has the industry's largest proprietary toolbox of genomic editors, allowing it to select optimal editing approaches for specific diseases.
The growth story
Arbor Biotechnologies grew from 59 to 100 employees between 2021 and 2026, raising $305M along the way, most recently a Series C in March 2025.
About
Arbor develops gene therapies by matching diseases to the most suitable gene editing tools from its extensive proprietary collection. Its approach lets researchers work backward from disease pathology rather than being limited to a single editing technology.
The company has raised $305M through Series C and draws talent heavily from pharmaceutical firms like Pfizer (6 hires) and CRISPR specialists like CRISPR Therapeutics (4). Its headcount stands at 100, with particularly strong representation from Boston-area research institutions.
Founders and leadership
Research dominates Arbor's workforce at 38% of headcount. Leadership includes alumni from the Broad Institute, a key CRISPR research center. The company maintains a median tenure of 2 years, typical for biotech startups.
The Arbor Biotechnologies org chart
Devyn Smith (Chief Executive Officer, CEO) leads 37 mapped leaders with 10 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 47 (-18% YoY), Business Development 13 (-13% YoY), Engineering 7 (-22% YoY), Operations 4 (-33% YoY), Information Technology 4 (0% YoY), Human Resources 3 (-25% YoY).
Talent flow
Arbor recruits heavily from Big Pharma (Pfizer, EMD Serono) and gene editing specialists (CRISPR Therapeutics). Alumni frequently move to Eli Lilly (6) and Moderna (3). Local universities like Northeastern and Tufts supply many researchers.
Most common previous employers of Arbor Biotechnologies staff: Pfizer (6), Tufts University (6), Broad Institute of MIT and Harvard (5), UMass Chan Medical School (4), EMD Serono (4), CRISPR Therapeutics (4). Former Arbor Biotechnologies employees most often moved to Eli Lilly and Company (6), WayBio (5), Moderna (3), Novo Nordisk (3), GSK (3), Genezen (2).
Alumni worth knowing
The Arbor Biotechnologies mafia
7 alumni-founded companies exist, including WayBio (3 founders) and Genezen (1 founder). Broad Institute connections are strong, with one founder and over 3,200 staff links to the CRISPR research hub.
9Winston Yan, MD PhD, was Co-Founder until 2025Steve Favaloro, was Chief Financial Officer until 2023Andy Harris, was Consultant until 2019Kaveh Daneshvar, was Senior Director, Head of Precision Editing until 2024Huaibin (Eli) Zhang, was Director, Core Services and Engineering until 2024Qiyuan Yang, was Senior Scientist until 2025
Seynedhee A., was Financial Planning Analyst until 2023
Kelly Davis, was Director, Performance Development & Enablement until 2025Web traffic
Traffic mix: 38% direct, 52% search, 0% social, 4% paid.
What this company is made of
Most common skills at Arbor Biotechnologies: Research Skills (36), Molecular Biology (33), Microsoft Office (28), Cell Culture (28), Polymerase Chain Reaction (PCR) (24), Western Blotting (24), Biotechnology (23), DNA Extraction (22).
Where the team actually sits
Arbor Biotechnologies people are concentrated in Massachusetts, United States (59), Greater Boston (20), United States (5), California, United States (1).
Search footprint
Arbor Biotechnologies attracts about 524 organic search visits a month, traffic worth roughly $2K a month if bought through ads. It gained 30 ranking keywords and lost 33 in the last period.
What employees say
- Compensation
- 3.30 / 5
- Career opportunities
- 3.00 / 5
- Senior management
- 2.70 / 5
- Work-life balance
- 3.30 / 5
Frequently asked
Arbor Biotechnologies has 100 employees as of September 2026.
Arbor Biotechnologies has raised $305M in total, most recently a Series C round in March 2025.
Arbor Biotechnologies was founded in 2016 by David Scott, David Walt.
Devyn Smith (Chief Executive Officer, CEO) sits at the top of Arbor Biotechnologies's reporting structure, with 10 direct reports.
The most common previous employers of current Arbor Biotechnologies staff are Pfizer (6 people), Tufts University (6 people), Broad Institute of MIT and Harvard (5 people).
Former Arbor Biotechnologies employees most often move to Eli Lilly and Company (6), WayBio (5), Moderna (3).
At least 7 companies have a founder who previously worked at Arbor Biotechnologies, including Broad Institute of MIT and Harvard, Genezen, Parallel Fluidics.
Arbor Biotechnologies attracts about 524 organic search visits a month, worth roughly $2K a month in equivalent ad spend.
The most common skills among Arbor Biotechnologies staff are Research Skills, Molecular Biology, Microsoft Office, Cell Culture, Polymerase Chain Reaction (PCR).
Arbor Biotechnologies staff are concentrated in Massachusetts, United States (59), Greater Boston (20), United States (5).
Arbor Biotechnologies has about 47 people in Research, down 18% over the past year, as of September 2026.
Arbor Biotechnologies has about 13 people in Business Development, down 13% over the past year, as of September 2026.
Computed from 85 current and 163 former Arbor Biotechnologies profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.